Background: The Polyflex™ is a commercially available silastic airway stent with proven efficacy. Due to a smooth outer surface its anchorage in the airway wall is superficial which may lead to stent migration. Objective: To study the performance of an newer version of the Polyflex stent with a studded outer surface, which should improve anchorage. Methods: In a 5-centre international study the new stent was prospectively tested in symptomatic patients with neoplastic central airway stenosis of more that 50% of normal diameter. Insertion technique, efficacy of stent placement and stent-related complications were recorded before, 1 month and 3 months post stent placement. Results: Under general anaesthesia and rigid bronchoscopy 27 stents were inserted in 26 patients, mean age: 62 years (range: 37–83), 16 men. Diagnoses were 18 bronchogenic carcinoma, 4 oesophageal carcinoma, 2 metastases, 1 tracheal carcinoma, and 1 schwannoma. The stents were inserted in the following locations: 10 right main bronchus, 8 left main bronchus, 7 trachea, and 2 tracheo-bronchial. There was significant improvement in all functional parameters assessed from before (A), to 1 month (B) and 3 months (C) after stent placement. The measured values (mean ± SD) were for the WHO scale: A: 2.7 (0.8), B: 1.5 (0.9), C: 1.6 (1.0); for the Karnofsky scale: A: 44 (19), B: 72 (18), C: 71 (21); for the Dyspnoea Index: A: 3.3 (0.7), B: 1.5 (0.8), C: 1.9 (1.2); for FEV1: A: 1.2 (0.5), B: 1.9 (0.6), C: 1.5 (0.5), and for FVC: A: 2.1 (0.7), B: 2.8 (0.7), C: 2.5 (1.0). Stent-related complications were 4 reversible stent obstructions by secretions, 1 migration. The observation period was mean 4.3 months (range 2 days to 23 months). Conclusion: The studded Polyflex showed excellent efficacy, was very well tolerated, and had a very low migration rate. It presents an improvement over the older smooth model and can be considered a true alternative to the most widely used silastic stent, the Dumon stent.

1.
Dumon JF: A dedicated tracheobronchial stent. Chest 1990;97:328–332.
2.
Bolliger CT, Probst R, Tschopp K, Soler M, Perruchoud AP: Silicone stents in the management of inoperable tracheobronchial stenoses. Indications and limitations. Chest 1993;104:1653–1659.
3.
Freitag L: Tracheobronchial stents; in Bolliger CT, Mathur PN (eds): Interventional Bronchoscopy. Prog Respir Res. Basel, Karger, 2000, vol 30, pp 171–186.
4.
Wassermann K, Koch A, Mueller-Ehmsen J, Reuter M, Michel O, Eckel HE: Clinical and laboratory evaluation of a new thin-walled self-expanding tracheobronchial silicone stent: Progress and pitfalls. J Thorac Cardiovasc Surg 1997;114:527–534.
5.
Wassermann K, Mathen F, Eckel HE: Concurrent glottic and tracheal stenoses: Restoration of airway continuity in end-stage malignant disease. Ann Otol Rhinol Laryngol 2001;110:349–355.
6.
Schildge J, Hauk H: Successful treatment of benign tracheal stenosis with a silicone stent (Polyflex-Stent) over 5 years. Pneumologie 2001;55:152–158.
7.
Bolliger CT, Wyser C, Wu X, Hauser R, Studer W, Dalquen P, Perruchoud AP: Evaluation of a new self-expandable silicone stent in an experimental tracheal stenosis. Chest 1999;115:496–501.
8.
Bolliger CT: Multimodality treatment of advanced pulmonary malignancies; in Bolliger CT, Mathur PN (eds): Interventional Bronchoscopy. Prog Respir Res. Basel Karger, 2000, vol 30, pp 187–196.
9.
Freitag L, Eicker K, Donovan TJ, Dimov D: Mechanical properties of airway stents. J Bronchol 1995;2:270–278.
10.
Bolliger CT, Heitz M, Hauser R, Probst R, Perruchoud AP: An airway wallstent for the treatment of tracheobronchial malignancies. Thorax 1996;51:1127–1129.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.